Pitobrutinib domestic launch time

Pirtobrutinib, trade name Jaypirca, is a non-covalent (reversible) brutinib-sensitive kinase (BTK) inhibitor developed by Lilly of the United States. The drug is primarily indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including BTK inhibitors, and patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Pitobrutinib inhibits BTK, a key molecule in the B cell receptor signaling pathway, and blocks the proliferation and survival signals of abnormal B cells, thereby achieving effective control of lymphoma.

The domestic launch of pitobrutinib is of great significance to lymphoma patients, but this drug is not currently on the domestic market. Clinical trial results of the drug showed that it showed good efficacy and safety in the treatment of relapsed or refractory mantle cell lymphoma as well as chronic lymphocytic leukemia or small lymphocytic lymphoma. The launch of pitobrutinib will provide a new treatment approach for these patients, which is expected to extend the patient's survival and improve their quality of life.

In addition, the launch of pitobrutinib will further promote the development of the domestic lymphoma treatment field. With the continuous emergence of new targeted drugs, the treatment of lymphoma is undergoing profound changes. Pitobrutinib, as the first approved non-covalent BTK inhibitor in China, will bring new treatment concepts and treatment methods to the domestic lymphoma treatment field, and help improve the overall diagnosis and treatment level of domestic lymphoma.

To sum up, the domestic launch of pitobrutinib is a great news for the field of lymphoma treatment. It will bring new treatment options to patients and will also promote the development of the domestic lymphoma treatment field. We expect that pitobrutinib will perform well in the domestic market and bring good news to more lymphoma patients.